1 December 2024 - The December 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are several new/revised listings of note this month:

• Lenvatinib mesylate (Lenvima) - new medicine
• Empagliflozin (Jardiance) - new indication
• Lisdexamphetamine mesylate (Vyvanse) - new medicine
• Methylphenidate hydrochloride (Rubifen, Ritalin, Concerta) - restriction change
• Dexamphetamine sulphate (Noumed Dexamfetamine) - restriction change
• Modafinil (Modafinil Max Health) - restriction change

Read New Zealand Pharmaceutical Schedule update